Table 2A.

Risk factors for grade III/IV aGvHD and mortality using univariable competing-risks Cox regression model

Risk Factor. N = 322 unless otherwise noted	Grade III–IV aGvHD (Events=63)		Early Mortality without Grade III/IV aGvHD (Events=25)
	HR	P	HR	P
Age at BMT (per 10 yr increase)	1.1 (0.9, 1.4)	0.24	0.9 (0.6,1.2)	0.37
Transplant Jan ’07–Dec ’09 vs. Jan’10–Jan’13	0.8 (0.5, 1.3)	0.39	3.6 (1.4, 9.6)	0.01
KPS score (≤ 80 vs. ≥ 90)	0.7 (0.4, 1.3)	0.23	1.0 (0.4, 2.4)	0.98
HCT on Admission (< 25% vs. ≥25%)	2.0 (1.1, 3.5)	0.02	1.2 (0.5, 3.2)	0.66
Disease risk (Low, Intermediate, High)		0.19		0.23
Intermediate vs. Low	0.9 (0.4, 1.7)	0.63	1.2 (0.4, 3.4)	0.76
High vs. Low	1.5 (0.9, 2.6)	0.16	2.1 (0.9, 5.2)	0.10
D/R Gender (Female to Male vs. other combinations)	1.4 (0.6, 2.0)	0.66	0.8 (0.3, 2.1)	0.58
Source (PBSC vs. BM)	0.8 (0.4, 1.6)	0.47	0.4 (0.2,1.0)	0.05
HLA Match (MM vs. Full)		0.025		0.40
10/10 Unrelated donor vs. 10/10 Sibling	1.5 (0.8, 2.7)	0.210	1.7 (0.7, 4.1)	0.20
<10/10 Match vs. 10/10 Sibling	2.4 (1.3, 4.6)	0.007	1.1 (0.3, 3.5)	0.91
ABO Match (MM vs. Match, N = 308)	1.2 (0.7, 1.9)	0.59	1.6 (0.7, 3.6)	0.29
Conditioning Regimen		0.38		0.73
Reduced Intensity vs. Nonmyeloablative	2.1 (0.7, 6.8)	0.20	1.0 (0.2, 4.3)	0.96
Myeloablative vs. Nonmyeloablative	2.3 (0.7, 7.3)	0.17	1.3 (0.3, 5.9)	0.72
Immune suppression CSA vs. FK506	1.1 (0.5, 2.1)	0.90	1.4 (0.5, 4.1)	0.54
Neutrophil engraft day: Median (≥ 15 vs. <15)	0.6 (0.4, 0.9)	0.03	0.8 (0.4, 1.7)	0.50
Platelet engraft day: Median (≥ 18 vs. < 18)	1.0 (0.6, 1.7)	0.89	5.6 (1.7, 18.5)	0.005
Avg age of RBC units (10d increment, N=288)	1.0 (0.6, 1.6)	1.00	0.4 (0.2, 0.8)	0.01
Pre-HSCT serum ferritin: Median (> 1146 vs. ≤ 1146 ng/ml, N=299)	0.6 (0.4, 1.0)	0.07	1.6 (0.7, 3.9)	0.29
RBC units (−7 to 27 days): Median (> 5 vs. ≤ 5)	2.4 (1.4, 4.1)	0.001	2.0 (0.9, 4.5)	0.09
Platelets (−7 to +27): Median (> 2 vs. ≤ 2)	1.6 (1.0, 2.6)	0.08	3.1 (1.3, 7.2)	0.009